IL-19, IL-20 and IL-24: Potential therapeutic targets for autoimmune diseases

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 2, 2011, Pages 119-126

  Leng, Rui Xue ^a   Pan, Hai Feng ^a   Tao, Jin Hui ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

autoimmunity; IL 19; IL 20; IL 24; therapeutic

Indexed keywords

INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 24;

AUTOIMMUNE DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; HUMAN; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; UVEITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKINS; MOLECULAR TARGETED THERAPY; PSORIASIS; RECEPTORS, INTERLEUKIN;

EID: 78651375087     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.534461     Document Type: Review

References (59)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid rthritis. Annu Rev Immunol 996;14:397-440
2. Firestein GS. Evolving concepts of heumatoid arthritis. Nature 003;423:356-61
3. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008;121:11081-1111
4. Witte K, Witte E, Sabat R, et al. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010;21:237-51
5. Donnelly RP, Sheikh F, Kotenko SV, et al. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004; 76:314-21
6. Langer JA, Cutrone EC, Kotenko S. The Class II cytokine receptor (CRF2)family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 2004;15:33-48
7. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006;17:367-80
8. Sabat R, Wallace E, Endesfelder S, et al. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 2007;11:601-12
9. Liao YC, Liang WG, Chen FW, et al. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 2002;169:4288-97
10. Chen PJ, Wei CC, Wang C, et al. Promoter analysis of interleukin 19. Biochem Biophys Res Commun 2006;344:713-20
11. Alanara T, Karstila K, Moilanen T, et al. Expression of IL-10 family cytokines in rheumatoid arthritis: elevated levels of IL-19 in the joints. Scand J Rheumatol 2010;39:118-26
12. Sakurai N, Kuroiwa T, Ikeuchi H, et al. Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation. Rheumatology 2008;47:815-20
13. Liao SC, Cheng YC, Wang YC, et al. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 2004;173:6712-18
14. Azuma YT, Matsuo Y, Kuwamura M, et al. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis 2010;16:1017-28
15. Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001;104:9-19
16. Wolk K, Kunz S, Asadullah K, et al. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002;168:5397-402
17. Grone A. Keratinocytes and cytokines. Vet Immunol Immunopathol 2002;88:1-12
18. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008;83:1181-93
19. Hsu YH, Li HH, Hsieh MY, et al. Function of interleukin-20 as a pro-inflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006;54:2722-33
20. Li HH, Cheng HH, Sun KH, et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol 2008;129:277-85
21. Parrish-Novak J, Xu W, Brender T, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes: differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002;277:47517-23
22. Rich BE. IL-20: a new target for the treatment of inflammatory skin disease. Expert Opin Ther Targets 2003;7:165-74
23. Jiang H, Lin JJ, Su ZZ, et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995;11:2477-86
24. Kreis S, Philippidou D, Margue C, et al. Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS One 2007;2:e1300
25. Kreis S, Philippidou D, Margue C, et al. IL-24: a classic cytokine and/or a potential cure for cancer? J Cell Mol Med 2008;12:2505-10
26. Kunz S, Wolk K, Witte E, et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006;15:991-1004
27. Andoh A, Shioya M, Nishida A, et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol 2009;183:687-95
28. Gupta P, Su ZZ, Lebedeva IV, et al. Mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006;111:596-628
29. Jiang H, Su ZZ, Lin JJ, et al. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996;93:9160-5
30. Otkjaer K, Kragballe K, Funding AT, et al. The dynamics of gene expression of interleukin- 19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 2005;153:911-18
31. Romer J, Hasselager E, Nørby PL, et al. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine A or calcipotriol. J Invest Dermatol 2003;121:1306-11
32. Li HH, Lin YC, Chen PJ, et al. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol 2005;153:591-5
33. Stenderup K, Rosada C, Worsaae A, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009;160:284-96
34. Koks S, Kingo K, Ratsep R, et al. Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun 2004;5:662-7
35. Kingo K, Mossner R, Ratsep R, et al. Association analysis of IL20RA and IL20RB genes in psoriasis. Genes Immun 2008;9:445-51
36. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40
37. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87
38. He M, Liang P. IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis. J Immunol 2010;184:1793-8
39. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87:523-36
40. Wolk K, Witte E, Warszawska K, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009;39:3570-81
41. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10
42. Oral HB, Kotenko SV, Yilmaz M, et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol 2006;36:380-8
43. Jordan WJ, Eskdale J, Boniotto M, et al. Human IL-19 regulates immunity through auto-induction of IL-19 and production of IL-10. Eur J Immunol 2005;35:1576-82
44. Tian Y, Sommerville LJ, Cuneo A, et al. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am J Pathol 2008;173:901-9
45. Kruglov AA, Kuchmiy A, Grivennikov SI, et al. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 2008;19:231-44
46. Fantuzzi F, Del Giglio M, Gisondi P, et al. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008;12:1085-96
47. Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010;62:430-40
48. Wahl C, Muller W, Leithauser F, et al. IL-20 receptor 2 signaling down-regulates antigen-specific T cell responses. J Immunol 2009;182:802-10
49. Kragstrup TW, Otkjaer K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine 2008;41:16-23
50. Tritsaris K, Myren M, Ditlev SB, et al. IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs. Proc Natl Acad Sci USA 2007;104:15364-9
51. Hsieh MY, Chen WY, Jiang MJ, et al. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006;7:234-42
52. Chen WY, Chang MS. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol 2009;182:5003-12
53. Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. Curr Opin Rheumatol 2002;14:498-503
54. Wei CC, Chang MS. A novel transcript of mouse interleukin-20 receptor acts on glomerular mesangial cells as an aggravating factor in lupus nephritis. Genes Immun 2008;9:668-79
55. Li HH, Hsu YH, Wei CC, et al. Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure. Genes Immun 2008;9:395-404
56. Li Z, Liu B, Maminishkis A, et al. Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol 2008;181:5147-57
57. Wolk K, Witte E, Reineke U, et al. Is there an interaction between interleukin-10 and interleukin-22? Genes Immun 2005;6:8-18
58. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004;21:241-5
59. Maarof G, Bouchet-Delbos L, Gary-Gouy H, et al. Interleukin-24 inhibits the plasma cell differentiation program in human germinal center B cells. Blood 2010;115:1718-26